Clinical efficacy of invimestrocel for acute respiratory distress syndrome caused by pneumonia: Comparison with historical data using propensity score analysis.

Summary

In pneumonia-induced ARDS, invimestrocel recipients had significantly more ventilator-free days and improved survival compared with a propensity score–matched historical cohort, supporting a potential therapeutic benefit of this cell-based intervention.

Key Findings

• Compared with matched historical controls (n=20), invimestrocel recipients (n=20) had higher ventilator-free days (14.8±11.0 vs 6.7±9.4; 95% CI 1.4–14.7; p=0.011).
• Survival was improved with invimestrocel (log-rank HR 0.330; 95% CI 0.116–0.938).
• Propensity score matching was applied to balance baseline characteristics between groups.

Clinical Implications

Invimestrocel may shorten ventilation duration and improve survival in pneumonia-induced ARDS; however, adoption requires confirmation in adequately powered randomized, blinded, placebo-controlled trials.

Limitations

• Small sample size (20 vs 20) and nonrandomized, historical comparison design.
• Potential residual confounding and selection bias despite matching; incomplete detailing of matching covariates in abstract.

Future Directions

Conduct randomized, blinded, placebo-controlled multicenter trials with predefined multiplicity control to confirm efficacy and safety and to identify responsive ARDS subphenotypes.